Plasmid DNA Manufacturing Market Market Analysis

By Product (Viral Vectors, Plasmid DNA, Lipid/Polymers, Nanoparticles)

The viral vector segment in the plasmid DNA manufacturing market has emerged as the dominant segment with a revenue share of 21.1% in 2023 owing to the growing demand for gene therapies and vaccines. Viral vectors are utilized as a tool which is involved in delivering genetic materials into the cell, and their usage has revolutionized the field of gene therapy and vaccine development.

There are also advancements in vector designing and manufacturing that have contributed to the growth of the plasmid DNA market by making it more efficient, reliable, and effective. Persistent innovation and discoveries have been spurred, collaborations between industry and academia, and government assistance in funding initiatives have fueled the propelled exploration.

In April 2024, Charles River Laboratories announced a collaboration with Axovia Therapeutics to produce high-quality gene of interest plasmids and extend its assistance in the development of procedure of gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS).

By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics)

Clinical therapeutics has positioned itself as a dominant segment, accounting for 55% of the plasmid DNA manufacturing market share in 2023. As the demand for gene therapy and vaccines continues to soar, this sector of market has capitalized on the trend, solidifying its position. With its strong pipeline of products and cutting-edge technologies, the clinical therapeutics sector is poised to drive growth and shape the future of plasmid DNA manufacturing market. For example, In December 2021, Plasmid DNA-based cancer immunotherapies, such as VGX-3100, have shown promising results in clinical trials.

By Disease (Cancer, Infectious Disease, Genetic disorder, other)

The oncology segment in the plasmid DNA manufacturing market is expected to account for the largest revenue share during the forecast period. This segment is expanding as a result of the increased use of DNA plasmids in cancer treatments. Numerous gene therapy approaches, inclusive of oncolytic virotherapy, immune modulation based on gene therapy, and genetic modification of apoptotic cells, are used to treat cancer. Thus, there’s a greater need for plasmid DNA, the driving force behind segment growth. Rare genetic disorders, such as sickle cell anemia and muscular dystrophy are also being targeted for expected results.

Our in-depth analysis of the plasmid DNA manufacturing market includes the following segments